Loading...
Docoh

ProPhase Labs (PRPH)

ProPhase Labs is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand. The Company is also developing ProPhase Diagnostics, Inc. ("ProPhase Diagnostics") to offer COVID-19 and other Respiratory Pathogen Panel (RPP) Molecular tests. The Company also continues to actively pursue strategic investments and acquisition opportunities for other companies, technologies and products.

Company profile

Ticker
PRPH
Exchange
CEO
Ted William Karkus
Employees
Incorporated
Location
Fiscal year end
Former names
QUIGLEY CORP
SEC CIK
Subsidiaries
Pharmaloz Manufacturing Inc. • ProPhase Digital Media, Inc. • ProPhase Diagnostics, Inc. • ProPhase Diagnostics NJ, Inc. • ProPhase Diagnostics NY, Inc. • Quigley Pharma Inc. • TK Supplements, Inc. • ProPhase Precision Medicine, Inc. • ProPhase Global Healthcare, Inc. ...
IRS number
232577138

PRPH stock data

Analyst ratings and price targets

Last 3 months
HC Wainwright & Co.
Maintains
Buy
$14.00
17 May 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Aug 22
16 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 24M 24M 24M 24M 24M 24M
Cash burn (monthly) 600K (no burn) (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 942.23K n/a n/a n/a n/a n/a
Cash remaining 23.06M n/a n/a n/a n/a n/a
Runway (months of cash) 38.4 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Aug 22 Karkus Ted William Common Stock, par value $0.005 Payment of exercise Dispose F No No 10.84 316,605 3.43M 2,788,609
10 Aug 22 Karkus Ted William Common Stock, par value $0.005 Option exercise Acquire M No No 0.6 600,000 360K 3,105,214
10 Aug 22 Karkus Ted William Option Common Stock Option exercise Dispose M No No 0.6 600,000 360K 1,700,000
1 Jul 22 Warren Hirsch Option Common Stock Grant Acquire A No No 12.92 40,000 516.8K 40,000
1 Jul 22 Gleckel Louis MD Option Common Stock Grant Acquire A No No 12.92 40,000 516.8K 40,000
1 Jul 22 Barr Jason Michael Option Common Stock Grant Acquire A No No 12.92 40,000 516.8K 40,000
9.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 22 26 -15.4%
Opened positions 0 10 EXIT
Closed positions 4 6 -33.3%
Increased positions 8 5 +60.0%
Reduced positions 7 4 +75.0%
13F shares Current Prev Q Change
Total value 10.77M 10.82M -0.5%
Total shares 1.54M 1.51M +1.9%
Total puts 29.5K 31.2K -5.4%
Total calls 0 22.1K EXIT
Total put/call ratio Infinity 1.4 +Infinity%
Largest owners Shares Value Change
Vanguard 512.61K $3.59M +2.9%
Renaissance Technologies 222.61K $1.56M -2.2%
Perritt Capital Management 208.4K $1.46M -0.2%
STA Wealth Management 140.34K $982K +17.2%
AMP Ameriprise Financial 137.94K $965K +2.4%
Geode Capital Management 105.86K $740K 0.0%
BK Bank Of New York Mellon 42.79K $300K -12.7%
STT State Street 31.06K $217K +14.2%
BAC Bank Of America 29.35K $205K +2.6%
BLK Blackrock 25.82K $180K -3.3%
Largest transactions Shares Bought/sold Change
STA Wealth Management 140.34K +20.59K +17.2%
Vanguard 512.61K +14.67K +2.9%
Susquehanna International 11.43K +11.43K NEW
Citadel Advisors 17.93K -10.52K -37.0%
BK Bank Of New York Mellon 42.79K -6.21K -12.7%
Renaissance Technologies 222.61K -5K -2.2%
STT State Street 31.06K +3.87K +14.2%
MS Morgan Stanley 2.89K -3.34K -53.6%
AMP Ameriprise Financial 137.94K +3.29K +2.4%
Group One Trading 5.07K +1.67K +49.1%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abandon, abroad, absence, adapt, administer, Affordable, Alzheimer, amenable, apparent, art, assert, assignee, assignor, attained, attaining, BioLife, biologic, biopharma, biopharmaceutical, biotechnology, black, block, box, breadth, broadening, broadly, candidate, cease, CFO, chemistry, clarify, clearance, client, CMC, combating, competitor, complementary, compound, concentrated, conclusion, confusion, constitute, contemplate, convenience, convenient, copying, costly, country, death, defense, delay, delayed, dementia, demonstrate, deny, deprive, desirable, desired, developmental, devote, difficulty, disagree, disagreeing, discover, discovery, discretion, dispersed, drop, editing, educate, eliminated, encounter, enroll, enrolled, enrolling, enrollment, Equivir, EU, exert, exploit, export, extinguished, extracting, facilitate, factual, focused, force, forgo, found, gap, GRDG, half, heterogeneity, hinder, hire, hold, holding, illustrative, impractical, improperly, Inadequate, inadvertently, inconclusive, increasingly, IND, ineligible, inflammatory, infringe, infringement, infringing, injury, insert, inside, inspect, intellectual, intense, internationally, introduction, invalid, invalidate, invalidated, IP, irrevocable, kinase, lag, lengthy, Lessor, Licensor, lifespan, Linebacker, literature, member, misappropriated, misappropriating, misappropriation, misplaced, moderately, molecule, mutual, narrowed, NDA, NGS, nonclinical, notwithstanding, novelty, opportunity, opposition, outweigh, payor, PBIO, pending, permanent, perpetual, pharmaceutical, phase, PIM, population, postpone, preclinical, preclude, prematurely, prescription, pressure, prevailing, profile, prohibit, prohibitively, prosecute, prosecuting, protocol, proximity, publish, published, publishing, purpose, pursuit, question, recordkeeping, recoup, recruit, recruited, recruiting, recruitment, reexamination, referral, reform, regular, relaxation, relinquish, render, rendering, reposition, resolve, resource, royalty, safe, safer, satisfaction, scientific, secret, selected, shortly, show, shown, side, Similarly, site, small, sophisticated, sought, specialty, spread, sq, stage, statistical, storage, strong, study, substitute, superior, susceptible, suspend, suspended, target, targeted, targeting, team, therapeutic, thereof, timeline, trial, turn, type, unacceptable, unchallenged, uncured, underperformed, undesirable, uneconomical, unenforceable, unexpected, unforeseen, unintended, unlicensed, unnecessarily, unplanned, unreasonable, unreasonably, unrestricted, unsolved, unsuccessful, upfront, USPTO, valuable, verification, viable, viewed, voluntarily, WGS, withdraw, withdrawing, withheld, withholding, writing, yield